[00:00:02.056] Server  LOG      ✓ Ready in 1189ms
[00:00:05.174] Server  LOG      ○ Compiling /analysis ...
[00:00:10.522] Browser INFO    %cDownload the React DevTools for a better development experience: https://react.dev/link/react-devtools font-weight:bold
[00:00:10.956] Browser ERROR   A tree hydrated but some attributes of the server rendered HTML didn't match the client properties. This won't be patched up. This can happen if a SSR-ed Client Component used:

- A server/client branch `if (typeof window !== 'undefined')`.
- Variable input such as `Date.now()` or `Math.random()` which changes each time it's called.
- Date formatting in a user's locale which doesn't match the server.
- External changing data without sending a snapshot of it along with the HTML.
- Invalid HTML tag nesting.

It can also happen if the client has a browser extension installed which messes with the HTML before React loaded.

%s%s https://react.dev/link/hydration-mismatch 

  ...
    <HTTPAccessFallbackBoundary notFound={undefined} forbidden={undefined} unauthorized={undefined}>
      <RedirectBoundary>
        <RedirectErrorBoundary router={{...}}>
          <InnerLayoutRouter url="/analysis" tree={[...]} params={{}} cacheNode={{lazyData:null, ...}} ...>
            <SegmentViewNode type="page" pagePath="/OneDrive/...">
              <SegmentTrieNode>
              <ClientPageRoot Component={function AnalysisPage} serverProvidedParams={{...}}>
                <AnalysisPage params={Promise} searchParams={Promise}>
                  <div className="min-h-scre...">
                    <AnalysisHeader>
                      <header className="fixed top-...">
                        <div className="max-w-7xl ...">
                          <LinkComponent>
                          <div className="flex items...">
                            <Button variant="ghost" size="sm">
                              <button
                                data-slot="button"
                                className={"inline-flex items-center justify-center whitespace-nowrap text-sm font-me..."}
-                               fdprocessedid="ydner"
                              >
+                               Help
                            <Button variant="outline" size="sm">
                              <button
                                data-slot="button"
                                className={"inline-flex items-center justify-center whitespace-nowrap text-sm font-me..."}
-                               fdprocessedid="6bms3"
                              >
+                               Export
                    ...
                      <div data-slot="card" className="bg-card te...">
                        <CardHeader>
                        <CardContent className="px-0 pt-6">
                          <div data-slot="card-content" className="px-0 pt-6">
                            <form onSubmit={function handleSubmit} className="space-y-4">
                              <div>
                              <div className="grid grid-...">
                                <div>
                                  <label>
                                  <input
                                    id="molecule"
                                    type="text"
                                    placeholder="e.g., Aspirin"
                                    value=""
                                    onChange={function onChange}
                                    className="w-full px-4 py-2 rounded-lg border border-input bg-background text-fore..."
                                    disabled={false}
-                                   fdprocessedid="2fuass"
                                  >
                                <div>
                                  <label>
                                  <select
                                    id="geography"
                                    value="Global"
                                    onChange={function onChange}
                                    className="w-full px-4 py-2 rounded-lg border border-input bg-background text-fore..."
                                    disabled={false}
-                                   fdprocessedid="l8rmms"
                                  >
                              ...
            ...
          ...

[00:00:10.956] Browser LOG     %c[Vercel Web Analytics]%c Debug mode is enabled by default in development. No requests will be sent to the server. color: rgb(120, 120, 120) color: inherit
[00:00:10.956] Browser LOG     %c[Vercel Web Analytics]%c Running queued event color: rgb(120, 120, 120) color: inherit pageview {"path":"/analysis","route":"/analysis"}
[00:00:10.956] Browser LOG     %c[Vercel Web Analytics]%c [pageview] http://localhost:3000/analysis color: rgb(120, 120, 120) color: inherit {"dp":"/analysis","o":"http://localhost:3000/analysis","sdkn":"@vercel/analytics/next","sdkv":"1.6.1","sv":"0.1.3","ts":1765294834230}
[00:00:34.696] Server  LOG     [API Route] FastAPI response: "{\n  \"success\": true,\n  \"molecule\": \"Drugs\",\n  \"results\": {\n    \"molecule\": \"Drugs\",\n    \"geography\": \"Global\",\n    \"iqvia\": {\n      \"success\": false,\n      \"report\": null,\n      \"error\": \"429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \\n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\\nPlease retry in 6.286161694s. [links {\\n  description: \\\"Learn more about Gemini API quotas\\\"\\n  url: \\\"https://ai.google.dev/gemini-api/docs/rate-limits\\\"\\n}\\n, violations {\\n  quota_metric: \\\"generativelanguage.googleapis.com/generate_content_free_tier_requests\\\"\\n  quota_id: \\\"GenerateRequestsPerDayPerProjectPerModel-FreeTier\\\"\\n  quota_dimensions {\\n    key: \\\"model\\\"\\n    value: \\\"gemini-2.5-flash\\\"\\n  }\\n  quota_dimensions {\\n    key: \\\"location\\\"\\n    value: \\\"global\\\"\\n  }\\n  quota_value: 20\\n}\\n, retry_delay {\\n  seconds: 6\\n}\\n]\"\n    },\n    \"clinical_trials\": {\n      \"success\": true,\n      \"report\": \"## Clinical Trials Report: Drugs\\n\\nThis report provides a comprehensive overview of the clinical trial landscape for the molecule \\\"Drugs,\\\" based on the provided real-world data.\\n\\n---\\n\\n### 1. Total Trials\\n\\nA total of **500** clinical trials have been conducted or are ongoing for \\\"Drugs.\\\"\\n\\n---\\n\\n### 2. Phase Distribution\\n\\nThe trials for \\\"Drugs\\\" are distributed across various phases as follows:\\n\\n*   **Phase 1 (including Early Phase 1):** 103 trials (93 Phase 1 + 10 Early Phase 1)\\n*   **Phase 2:** 99 trials\\n*   **Phase 3:** 53 trials\\n*   **Phase 4:** 37 trials\\n*   **NA (Not Applicable/Phase not specified):** 133 trials\\n*   **Unknown:** 75 trials\\n\\n---\\n\\n### 3. Status Distribution\\n\\nThe current status of the clinical trials for \\\"Drugs\\\" is:\\n\\n*   **COMPLETED:** 281 trials\\n*   **UNKNOWN:** 60 trials\\n*   **RECRUITING:** 60 trials\\n*   **TERMINATED:** 42 trials\\n*   **ACTIVE_NOT_RECRUITING:** 24 trials\\n*   **NOT_YET_RECRUITING:** 17 trials\\n*   **WITHDRAWN:** 13 trials\\n*   **SUSPENDED:** 2 trials\\n*   **ENROLLING_BY_INVITATION:** 1 trial\\n\\n---\\n\\n### 4. Top 5 Sponsors\\n\\nThe leading sponsors for clinical trials involving \\\"Drugs\\\" are:\\n\\n1.  **Pfizer (10 trials):** A major global pharmaceutical corporation, Pfizer's significant number of trials indicates a strong strategic interest and investment in the development of \\\"Drugs.\\\"\\n2.  **Novartis Pharmaceuticals (8 trials):** Another prominent multinational pharmaceutical company, Novartis's involvement highlights its commitment to exploring the therapeutic potential of this molecule.\\n3.  **National Cancer Institute (NCI) (6 trials):** As a leading federal agency for cancer research, NCI's trials suggest a focus on oncology applications for \\\"Drugs,\\\" often involving collaborative academic and institutional efforts.\\n4.  **M.D. Anderson Cancer Center (5 trials):** A renowned cancer treatment and research institution, its trials likely contribute to cutting-edge research, particularly in cancer-related indications.\\n5.  **AstraZeneca (5 trials):** A global biopharmaceutical company, AstraZeneca's trials signify its engagement in the development pipeline for \\\"Drugs,\\\" potentially across various therapeutic areas.\\n\\n---\\n\\n### 5. Yearwise Trend Table (Start Dates)\\n\\n| Year | Number of Trials |\\n| :--- | :--------------- |\\n| 1995 | 1                |\\n| 1996 | 1                |\\n| 1998 | 2                |\\n| 2000 | 3                |\\n| 2001 | 3                |\\n| 2002 | 4                |\\n| 2003 | 7                |\\n| 2004 | 5                |\\n| 2005 | 5                |\\n| 2006 | 9                |\\n| 2007 | 10               |\\n| 2008 | 17               |\\n| 2009 | 17               |\\n| 2010 | 15               |\\n| 2011 | 18               |\\n| 2012 | 14               |\\n| 2013 | 18               |\\n| 2014 | 19               |\\n| 2015 | 20               |\\n| 2016 | 28               |\\n| 2017 | 36               |\\n| 2018 | 20               |\\n| 2019 | 28               |\\n| 2020 | 38               |\\n| 2021 | 33               |\\n| 2022 | 32               |\\n| 2023 | 31               |\\n| 2024 | 25               |\\n| 2025 | 37               |\\n| 2026 | 1                |\\n| Unknown | 3                |\\n\\n---\\n\\n### 6. Top Countries Conducting Trials\\n\\nThe countries with the highest number of clinical trials for \\\"Drugs\\\" are:\\n\\n1.  **United States:** 211 trials\\n2.  **China:** 53 trials\\n3.  **Canada:** 35 trials\\n4.  **Germany:** 34 trials\\n5.  **United Kingdom:** 27 trials\\n6.  **Italy:** 24 trials\\n7.  **France:** 24 trials\\n\\n---\\n\\n### 7. Enrollment Analysis\\n\\nThe total enrollment across all recorded clinical trials for \\\"Drugs\\\" is **1,614,624** participants. This substantial number indicates a widespread and significant research effort, suggesting the molecule is being investigated for conditions affecting a large patient population or across numerous studies.\\n\\n---\\n\\n### 8. Clinical Landscape Summary\\n\\nThe clinical landscape for \\\"Drugs\\\" is active, with 500 trials and a substantial total enrollment of over 1.6 million participants. While a large portion of trials are completed (281), a significant number are still recruiting (60) or active (24), indicating ongoing research. Early-phase development (Phase 1 and 2) shows considerable activity with 202 trials, suggesting a pipeline of new investigations. Global pharmaceutical giants like Pfizer and Novartis, alongside major academic and government institutions such as NCI and M.D. Anderson, lead sponsorship. The United States dominates trial locations, followed by China and European nations, reflecting a broad international research footprint.\",\n      \"error\": null\n    },\n    \"patents\": {\n      \"success\": false,\n      \"report\": null,\n      \"error\": \"429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \\n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\\nPlease retry in 11.931270342s. [links {\\n  description: \\\"Learn more about Gemini API quotas\\\"\\n  url: \\\"https://ai.google.dev/gemini-api/docs/rate-limits\\\"\\n}\\n, violations {\\n  quota_metric: \\\"generativelanguage.googleapis.com/generate_content_free_tier_requests\\\"\\n  quota_id: \\\"GenerateRequestsPerDayPerProjectPerModel-FreeTier\\\"\\n  quota_dimensions {\\n    key: \\\"model\\\"\\n    value: \\\"gemini-2.5-flash\\\"\\n  }\\n  quota_dimensions {\\n    key: \\\"location\\\"\\n    value: \\\"global\\\"\\n  }\\n  quota_value: 20\\n}\\n, retry_delay {\\n  seconds: 11\\n}\\n]\"\n    },\n    \"exim\": {\n      \"success\": false,\n      \"report\": null,\n      \"error\": \"429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \\n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\\nPlease retry in 2.764429817s. [links {\\n  description: \\\"Learn more about Gemini API quotas\\\"\\n  url: \\\"https://ai.google.dev/gemini-api/docs/rate-limits\\\"\\n}\\n, violations {\\n  quota_metric: \\\"generativelanguage.googleapis.com/generate_content_free_tier_requests\\\"\\n  quota_id: \\\"GenerateRequestsPerDayPerProjectPerModel-FreeTier\\\"\\n  quota_dimensions {\\n    key: \\\"model\\\"\\n    value: \\\"gemini-2.5-flash\\\"\\n  }\\n  quota_dimensions {\\n    key: \\\"location\\\"\\n    value: \\\"global\\\"\\n  }\\n  quota_value: 20\\n}\\n, retry_delay {\\n  seconds: 2\\n}\\n]\"\n    },\n    \"web_intel\": {\n      \"success\": false,\n      \"report\": null,\n      \"error\": \"429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \\n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\\nPlease retry in 10.39410824s. [links {\\n  description: \\\"Learn more about Gemini API quotas\\\"\\n  url: \\\"https://ai.google.dev/gemini-api/docs/rate-limits\\\"\\n}\\n, violations {\\n  quota_metric: \\\"generativelanguage.googleapis.com/generate_content_free_tier_requests\\\"\\n  quota_id: \\\"GenerateRequestsPerDayPerProjectPerModel-FreeTier\\\"\\n  quota_dimensions {\\n    key: \\\"model\\\"\\n    value: \\\"gemini-2.5-flash\\\"\\n  }\\n  quota_dimensions {\\n    key: \\\"location\\\"\\n    value: \\\"global\\\"\\n  }\\n  quota_value: 20\\n}\\n, retry_delay {\\n  seconds: 10\\n}\\n]\"\n    },\n    \"internal_knowledge\": {\n      \"success\": true,\n      \"report\": \"Error generating internal knowledge report: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \\n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\\nPlease retry in 13.633391609s. [links {\\n  description: \\\"Learn more about Gemini API quotas\\\"\\n  url: \\\"https://ai.google.dev/gemini-api/docs/rate-limits\\\"\\n}\\n, violations {\\n  quota_metric: \\\"generativelanguage.googleapis.com/generate_content_free_tier_requests\\\"\\n  quota_id: \\\"GenerateRequestsPerDayPerProjectPerModel-FreeTier\\\"\\n  quota_dimensions {\\n    key: \\\"model\\\"\\n    value: \\\"gemini-2.5-flash\\\"\\n  }\\n  quota_dimensions {\\n    key: \\\"location\\\"\\n    value: \\\"global\\\"\\n  }\\n  quota_value: 20\\n}\\n, retry_delay {\\n  seconds: 13\\n}\\n]\",\n      \"error\": null\n    }\n  },\n  \"updates\": [\n    {\n      \"agent\": \"Master Agent\",\n      \"status\": \"running\",\n      \"message\": \"Analyzing query for molecule: Drugs\",\n      \"data\": null\n    },\n    {\n      \"agent\": \"IQVIA Insights Agent\",\n      \"status\": \"running\",\n      \"message\": \"Fetching market data and insights...\",\n      \"data\": null\n    },\n    {\n      \"agent\": \"Clinical Trials Agent\",\n      \"status\": \"running\",\n      \"message\": \"Searching clinical trials database...\",\n      \"data\": null\n    },\n    {\n      \"agent\": \"Patent Agent\",\n      \"status\": \"running\",\n      \"message\": \"Analyzing patent landscape...\",\n      \"data\": null\n    },\n    {\n      \"agent\": \"EXIM Agent\",\n      \"status\": \"running\",\n      \"message\": \"Checking export/import opportunities...\",\n      \"data\": null\n    },\n    {\n      \"agent\": \"Web Intelligence Agent\",\n      \"status\": \"running\",\n      \"message\": \"Gathering web insights and news...\",\n      \"data\": null\n    },\n    {\n      \"agent\": \"Internal Knowledge Agent\",\n      \"status\": \"running\",\n      \"message\": \"Analyzing internal knowledge base...\",\n      \"data\": null\n    },\n    {\n      \"agent\": \"Master Agent\",\n      \"status\": \"completed\",\n      \"message\": \"All agents completed analysis\",\n      \"data\": null\n    },\n    {\n      \"agent\": \"Report Generator Agent\",\n      \"status\": \"completed\",\n      \"message\": \"Analysis complete. Dashboard updated with insights.\",\n      \"data\": null\n    }\n  ]\n}"
[00:00:34.940] Browser LOG     [AnalysisPage] Full response data: {"molecule":"Drugs","results":{"clinical_trials":{"error":null,"report":"## Clinical Trials Report: Drugs\n\nThis report provides a comprehensive overview of the clinical trial landscape for the molecule \"Drugs,\" based on the provided real-world data.\n\n---\n\n### 1. Total Trials\n\nA total of **500** clinical trials have been conducted or are ongoing for \"Drugs.\"\n\n---\n\n### 2. Phase Distribution\n\nThe trials for \"Drugs\" are distributed across various phases as follows:\n\n*   **Phase 1 (including Early Phase 1):** 103 trials (93 Phase 1 + 10 Early Phase 1)\n*   **Phase 2:** 99 trials\n*   **Phase 3:** 53 trials\n*   **Phase 4:** 37 trials\n*   **NA (Not Applicable/Phase not specified):** 133 trials\n*   **Unknown:** 75 trials\n\n---\n\n### 3. Status Distribution\n\nThe current status of the clinical trials for \"Drugs\" is:\n\n*   **COMPLETED:** 281 trials\n*   **UNKNOWN:** 60 trials\n*   **RECRUITING:** 60 trials\n*   **TERMINATED:** 42 trials\n*   **ACTIVE_NOT_RECRUITING:** 24 trials\n*   **NOT_YET_RECRUITING:** 17 trials\n*   **WITHDRAWN:** 13 trials\n*   **SUSPENDED:** 2 trials\n*   **ENROLLING_BY_INVITATION:** 1 trial\n\n---\n\n### 4. Top 5 Sponsors\n\nThe leading sponsors for clinical trials involving \"Drugs\" are:\n\n1.  **Pfizer (10 trials):** A major global pharmaceutical corporation, Pfizer's significant number of trials indicates a strong strategic interest and investment in the development of \"Drugs.\"\n2.  **Novartis Pharmaceuticals (8 trials):** Another prominent multinational pharmaceutical company, Novartis's involvement highlights its commitment to exploring the therapeutic potential of this molecule.\n3.  **National Cancer Institute (NCI) (6 trials):** As a leading federal agency for cancer research, NCI's trials suggest a focus on oncology applications for \"Drugs,\" often involving collaborative academic and institutional efforts.\n4.  **M.D. Anderson Cancer Center (5 trials):** A renowned cancer treatment and research institution, its trials likely contribute to cutting-edge research, particularly in cancer-related indications.\n5.  **AstraZeneca (5 trials):** A global biopharmaceutical company, AstraZeneca's trials signify its engagement in the development pipeline for \"Drugs,\" potentially across various therapeutic areas.\n\n---\n\n### 5. Yearwise Trend Table (Start Dates)\n\n| Year | Number of Trials |\n| :--- | :--------------- |\n| 1995 | 1                |\n| 1996 | 1                |\n| 1998 | 2                |\n| 2000 | 3                |\n| 2001 | 3                |\n| 2002 | 4                |\n| 2003 | 7                |\n| 2004 | 5                |\n| 2005 | 5                |\n| 2006 | 9                |\n| 2007 | 10               |\n| 2008 | 17               |\n| 2009 | 17               |\n| 2010 | 15               |\n| 2011 | 18               |\n| 2012 | 14               |\n| 2013 | 18               |\n| 2014 | 19               |\n| 2015 | 20               |\n| 2016 | 28               |\n| 2017 | 36               |\n| 2018 | 20               |\n| 2019 | 28               |\n| 2020 | 38               |\n| 2021 | 33               |\n| 2022 | 32               |\n| 2023 | 31               |\n| 2024 | 25               |\n| 2025 | 37               |\n| 2026 | 1                |\n| Unknown | 3                |\n\n---\n\n### 6. Top Countries Conducting Trials\n\nThe countries with the highest number of clinical trials for \"Drugs\" are:\n\n1.  **United States:** 211 trials\n2.  **China:** 53 trials\n3.  **Canada:** 35 trials\n4.  **Germany:** 34 trials\n5.  **United Kingdom:** 27 trials\n6.  **Italy:** 24 trials\n7.  **France:** 24 trials\n\n---\n\n### 7. Enrollment Analysis\n\nThe total enrollment across all recorded clinical trials for \"Drugs\" is **1,614,624** participants. This substantial number indicates a widespread and significant research effort, suggesting the molecule is being investigated for conditions affecting a large patient population or across numerous studies.\n\n---\n\n### 8. Clinical Landscape Summary\n\nThe clinical landscape for \"Drugs\" is active, with 500 trials and a substantial total enrollment of over 1.6 million participants. While a large portion of trials are completed (281), a significant number are still recruiting (60) or active (24), indicating ongoing research. Early-phase development (Phase 1 and 2) shows considerable activity with 202 trials, suggesting a pipeline of new investigations. Global pharmaceutical giants like Pfizer and Novartis, alongside major academic and government institutions such as NCI and M.D. Anderson, lead sponsorship. The United States dominates trial locations, followed by China and European nations, reflecting a broad international research footprint.","success":true},"exim":{"error":"429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\nPlease retry in 2.764429817s. [links {\n  description: \"Learn more about Gemini API quotas\"\n  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n}\n, violations {\n  quota_metric: \"generativelanguage.googleapis.com/generate_content_free_tier_requests\"\n  quota_id: \"GenerateRequestsPerDayPerProjectPerModel-FreeTier\"\n  quota_dimensions {\n    key: \"model\"\n    value: \"gemini-2.5-flash\"\n  }\n  quota_dimensions {\n    key: \"location\"\n    value: \"global\"\n  }\n  quota_value: 20\n}\n, retry_delay {\n  seconds: 2\n}\n]","report":null,"success":false},"geography":"Global","internal_knowledge":{"error":null,"report":"Error generating internal knowledge report: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\nPlease retry in 13.633391609s. [links {\n  description: \"Learn more about Gemini API quotas\"\n  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n}\n, violations {\n  quota_metric: \"generativelanguage.googleapis.com/generate_content_free_tier_requests\"\n  quota_id: \"GenerateRequestsPerDayPerProjectPerModel-FreeTier\"\n  quota_dimensions {\n    key: \"model\"\n    value: \"gemini-2.5-flash\"\n  }\n  quota_dimensions {\n    key: \"location\"\n    value: \"global\"\n  }\n  quota_value: 20\n}\n, retry_delay {\n  seconds: 13\n}\n]","success":true},"iqvia":{"error":"429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\nPlease retry in 6.286161694s. [links {\n  description: \"Learn more about Gemini API quotas\"\n  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n}\n, violations {\n  quota_metric: \"generativelanguage.googleapis.com/generate_content_free_tier_requests\"\n  quota_id: \"GenerateRequestsPerDayPerProjectPerModel-FreeTier\"\n  quota_dimensions {\n    key: \"model\"\n    value: \"gemini-2.5-flash\"\n  }\n  quota_dimensions {\n    key: \"location\"\n    value: \"global\"\n  }\n  quota_value: 20\n}\n, retry_delay {\n  seconds: 6\n}\n]","report":null,"success":false},"molecule":"Drugs","patents":{"error":"429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\nPlease retry in 11.931270342s. [links {\n  description: \"Learn more about Gemini API quotas\"\n  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n}\n, violations {\n  quota_metric: \"generativelanguage.googleapis.com/generate_content_free_tier_requests\"\n  quota_id: \"GenerateRequestsPerDayPerProjectPerModel-FreeTier\"\n  quota_dimensions {\n    key: \"model\"\n    value: \"gemini-2.5-flash\"\n  }\n  quota_dimensions {\n    key: \"location\"\n    value: \"global\"\n  }\n  quota_value: 20\n}\n, retry_delay {\n  seconds: 11\n}\n]","report":null,"success":false},"web_intel":{"error":"429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\nPlease retry in 10.39410824s. [links {\n  description: \"Learn more about Gemini API quotas\"\n  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n}\n, violations {\n  quota_metric: \"generativelanguage.googleapis.com/generate_content_free_tier_requests\"\n  quota_id: \"GenerateRequestsPerDayPerProjectPerModel-FreeTier\"\n  quota_dimensions {\n    key: \"model\"\n    value: \"gemini-2.5-flash\"\n  }\n  quota_dimensions {\n    key: \"location\"\n    value: \"global\"\n  }\n  quota_value: 20\n}\n, retry_delay {\n  seconds: 10\n}\n]","report":null,"success":false}},"success":true,"updates":[{"agent":"Master Agent","data":null,"message":"Analyzing query for molecule: Drugs","status":"running"},{"agent":"IQVIA Insights Agent","data":null,"message":"Fetching market data and insights...","status":"running"},{"agent":"Clinical Trials Agent","data":null,"message":"Searching clinical trials database...","status":"running"},{"agent":"Patent Agent","data":null,"message":"Analyzing patent landscape...","status":"running"},{"agent":"EXIM Agent","data":null,"message":"Checking export/import opportunities...","status":"running"},{"agent":"Web Intelligence Agent","data":null,"message":"Gathering web insights and news...","status":"running"},{"agent":"Internal Knowledge Agent","data":null,"message":"Analyzing internal knowledge base...","status":"running"},{"agent":"Master Agent","data":null,"message":"All agents completed analysis","status":"completed"},{"agent":"Report Generator Agent","data":null,"message":"Analysis complete. Dashboard updated with insights.","status":"completed"}]}
[00:00:34.941] Browser LOG     [AnalysisPage] Results: {"clinical_trials":{"error":null,"report":"## Clinical Trials Report: Drugs\n\nThis report provides a comprehensive overview of the clinical trial landscape for the molecule \"Drugs,\" based on the provided real-world data.\n\n---\n\n### 1. Total Trials\n\nA total of **500** clinical trials have been conducted or are ongoing for \"Drugs.\"\n\n---\n\n### 2. Phase Distribution\n\nThe trials for \"Drugs\" are distributed across various phases as follows:\n\n*   **Phase 1 (including Early Phase 1):** 103 trials (93 Phase 1 + 10 Early Phase 1)\n*   **Phase 2:** 99 trials\n*   **Phase 3:** 53 trials\n*   **Phase 4:** 37 trials\n*   **NA (Not Applicable/Phase not specified):** 133 trials\n*   **Unknown:** 75 trials\n\n---\n\n### 3. Status Distribution\n\nThe current status of the clinical trials for \"Drugs\" is:\n\n*   **COMPLETED:** 281 trials\n*   **UNKNOWN:** 60 trials\n*   **RECRUITING:** 60 trials\n*   **TERMINATED:** 42 trials\n*   **ACTIVE_NOT_RECRUITING:** 24 trials\n*   **NOT_YET_RECRUITING:** 17 trials\n*   **WITHDRAWN:** 13 trials\n*   **SUSPENDED:** 2 trials\n*   **ENROLLING_BY_INVITATION:** 1 trial\n\n---\n\n### 4. Top 5 Sponsors\n\nThe leading sponsors for clinical trials involving \"Drugs\" are:\n\n1.  **Pfizer (10 trials):** A major global pharmaceutical corporation, Pfizer's significant number of trials indicates a strong strategic interest and investment in the development of \"Drugs.\"\n2.  **Novartis Pharmaceuticals (8 trials):** Another prominent multinational pharmaceutical company, Novartis's involvement highlights its commitment to exploring the therapeutic potential of this molecule.\n3.  **National Cancer Institute (NCI) (6 trials):** As a leading federal agency for cancer research, NCI's trials suggest a focus on oncology applications for \"Drugs,\" often involving collaborative academic and institutional efforts.\n4.  **M.D. Anderson Cancer Center (5 trials):** A renowned cancer treatment and research institution, its trials likely contribute to cutting-edge research, particularly in cancer-related indications.\n5.  **AstraZeneca (5 trials):** A global biopharmaceutical company, AstraZeneca's trials signify its engagement in the development pipeline for \"Drugs,\" potentially across various therapeutic areas.\n\n---\n\n### 5. Yearwise Trend Table (Start Dates)\n\n| Year | Number of Trials |\n| :--- | :--------------- |\n| 1995 | 1                |\n| 1996 | 1                |\n| 1998 | 2                |\n| 2000 | 3                |\n| 2001 | 3                |\n| 2002 | 4                |\n| 2003 | 7                |\n| 2004 | 5                |\n| 2005 | 5                |\n| 2006 | 9                |\n| 2007 | 10               |\n| 2008 | 17               |\n| 2009 | 17               |\n| 2010 | 15               |\n| 2011 | 18               |\n| 2012 | 14               |\n| 2013 | 18               |\n| 2014 | 19               |\n| 2015 | 20               |\n| 2016 | 28               |\n| 2017 | 36               |\n| 2018 | 20               |\n| 2019 | 28               |\n| 2020 | 38               |\n| 2021 | 33               |\n| 2022 | 32               |\n| 2023 | 31               |\n| 2024 | 25               |\n| 2025 | 37               |\n| 2026 | 1                |\n| Unknown | 3                |\n\n---\n\n### 6. Top Countries Conducting Trials\n\nThe countries with the highest number of clinical trials for \"Drugs\" are:\n\n1.  **United States:** 211 trials\n2.  **China:** 53 trials\n3.  **Canada:** 35 trials\n4.  **Germany:** 34 trials\n5.  **United Kingdom:** 27 trials\n6.  **Italy:** 24 trials\n7.  **France:** 24 trials\n\n---\n\n### 7. Enrollment Analysis\n\nThe total enrollment across all recorded clinical trials for \"Drugs\" is **1,614,624** participants. This substantial number indicates a widespread and significant research effort, suggesting the molecule is being investigated for conditions affecting a large patient population or across numerous studies.\n\n---\n\n### 8. Clinical Landscape Summary\n\nThe clinical landscape for \"Drugs\" is active, with 500 trials and a substantial total enrollment of over 1.6 million participants. While a large portion of trials are completed (281), a significant number are still recruiting (60) or active (24), indicating ongoing research. Early-phase development (Phase 1 and 2) shows considerable activity with 202 trials, suggesting a pipeline of new investigations. Global pharmaceutical giants like Pfizer and Novartis, alongside major academic and government institutions such as NCI and M.D. Anderson, lead sponsorship. The United States dominates trial locations, followed by China and European nations, reflecting a broad international research footprint.","success":true},"exim":{"error":"429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\nPlease retry in 2.764429817s. [links {\n  description: \"Learn more about Gemini API quotas\"\n  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n}\n, violations {\n  quota_metric: \"generativelanguage.googleapis.com/generate_content_free_tier_requests\"\n  quota_id: \"GenerateRequestsPerDayPerProjectPerModel-FreeTier\"\n  quota_dimensions {\n    key: \"model\"\n    value: \"gemini-2.5-flash\"\n  }\n  quota_dimensions {\n    key: \"location\"\n    value: \"global\"\n  }\n  quota_value: 20\n}\n, retry_delay {\n  seconds: 2\n}\n]","report":null,"success":false},"geography":"Global","internal_knowledge":{"error":null,"report":"Error generating internal knowledge report: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\nPlease retry in 13.633391609s. [links {\n  description: \"Learn more about Gemini API quotas\"\n  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n}\n, violations {\n  quota_metric: \"generativelanguage.googleapis.com/generate_content_free_tier_requests\"\n  quota_id: \"GenerateRequestsPerDayPerProjectPerModel-FreeTier\"\n  quota_dimensions {\n    key: \"model\"\n    value: \"gemini-2.5-flash\"\n  }\n  quota_dimensions {\n    key: \"location\"\n    value: \"global\"\n  }\n  quota_value: 20\n}\n, retry_delay {\n  seconds: 13\n}\n]","success":true},"iqvia":{"error":"429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\nPlease retry in 6.286161694s. [links {\n  description: \"Learn more about Gemini API quotas\"\n  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n}\n, violations {\n  quota_metric: \"generativelanguage.googleapis.com/generate_content_free_tier_requests\"\n  quota_id: \"GenerateRequestsPerDayPerProjectPerModel-FreeTier\"\n  quota_dimensions {\n    key: \"model\"\n    value: \"gemini-2.5-flash\"\n  }\n  quota_dimensions {\n    key: \"location\"\n    value: \"global\"\n  }\n  quota_value: 20\n}\n, retry_delay {\n  seconds: 6\n}\n]","report":null,"success":false},"molecule":"Drugs","patents":{"error":"429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\nPlease retry in 11.931270342s. [links {\n  description: \"Learn more about Gemini API quotas\"\n  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n}\n, violations {\n  quota_metric: \"generativelanguage.googleapis.com/generate_content_free_tier_requests\"\n  quota_id: \"GenerateRequestsPerDayPerProjectPerModel-FreeTier\"\n  quota_dimensions {\n    key: \"model\"\n    value: \"gemini-2.5-flash\"\n  }\n  quota_dimensions {\n    key: \"location\"\n    value: \"global\"\n  }\n  quota_value: 20\n}\n, retry_delay {\n  seconds: 11\n}\n]","report":null,"success":false},"web_intel":{"error":"429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-2.5-flash\nPlease retry in 10.39410824s. [links {\n  description: \"Learn more about Gemini API quotas\"\n  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n}\n, violations {\n  quota_metric: \"generativelanguage.googleapis.com/generate_content_free_tier_requests\"\n  quota_id: \"GenerateRequestsPerDayPerProjectPerModel-FreeTier\"\n  quota_dimensions {\n    key: \"model\"\n    value: \"gemini-2.5-flash\"\n  }\n  quota_dimensions {\n    key: \"location\"\n    value: \"global\"\n  }\n  quota_value: 20\n}\n, retry_delay {\n  seconds: 10\n}\n]","report":null,"success":false}}
[00:00:34.941] Browser LOG     [AnalysisPage] Innovation opportunities: undefined
[00:00:34.941] Browser LOG     [InnovationConceptCard] Received data: undefined
[00:00:34.941] Browser LOG     [InnovationConceptCard] Data type: undefined
[00:00:34.941] Browser LOG     [InnovationConceptCard] Data success: undefined
[00:00:34.941] Browser LOG     [InnovationConceptCard] Data report: undefined
[00:00:34.941] Browser LOG     [InnovationConceptCard] Received data: undefined
[00:00:34.941] Browser LOG     [InnovationConceptCard] Data type: undefined
[00:00:34.941] Browser LOG     [InnovationConceptCard] Data success: undefined
[00:00:34.941] Browser LOG     [InnovationConceptCard] Data report: undefined
